Astellas Pharma Inc. Initiates Phase 3 Study for KRAS G12D Cancer Drug
1 report, 1 independent
Updated Sep 23
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Astellas Pharma Inc. named Naoki Okamura as its President and CEO on September 23, 2026. The company also announced that the first patient has been dosed in a Phase 3 study evaluating setidegrasib, a novel KRAS G12D-targeted protein degrader, for advanced non-small cell lung cancer (NSCLC).
From prnewswire.com
Why it matters
The Phase 3 study compares setidegrasib against docetaxel for patients whose NSCLC has progressed on initial chemotherapy and checkpoint inhibitor therapy. This research is significant because there are currently no approved therapies specifically for people with KRAS G12D mutations.
From prnewswire.com
Who's involved
- Naoki OkamuraPrincipal investigator at the Duke Cancer Institute and newly appointed President and CEO of Astellas Pharma Inc.
Keep exploring
The entities involved
-
Naoki Okamura
researcher
Nothing else this week.